XPH's 29% Run Looks Tempting, But The 5y Chart Is A Warning

SPDR S&P Pharmaceuticals ETF ( NYSEARCA:XPH ) exists to solve a specific problem: how do you gain broad exposure to pharmaceutical companies without the concentration risk of the largest healthcare names dominating your returns?

24/7 Wall Street • Feb 18, 2026

Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More

Big Pharma delivered strong Q4 2025 results, with most companies beating revenue and EPS expectations and providing generally solid 2026 guidance. Eli Lilly solidified its leadership in obesity and diabetes, outpacing Novo Nordisk, which faces a sharp 2026 revenue decline amid fierce competition, pricing pressure, and other factors.

Seeking Alpha • Feb 7, 2026

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Designed to provide broad exposure to the Health Care ETFs category of the market, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a smart beta exchange traded fund launched on 06/19/2006.

Zacks Investment Research • Jan 29, 2026

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

The State Street SPDR S&P Pharmaceuticals ETF (XPH) was launched on June 19, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.

Zacks Investment Research • Jan 28, 2026

XPH: Healthcare Dashboard For January

Healthcare providers have a good value score, and the pharmaceuticals & biotechnology subsector has a good quality score. State Street SPDR S&P Pharmaceuticals ETF provides modified equal-weighted exposure to the pharmaceutical industry, reducing company-specific risk versus cap-weighted peers. XPH is best suited for tactical allocation or swing trading, not as a long-term core holding, given its historical underperformance.

Seeking Alpha • Jan 16, 2026

Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts

As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much damage can Washington really do to Big Pharma's bottom line?

Benzinga • Dec 19, 2025

3 Undervalued ETFs to Buy Before 2026

Worried about high valuations? KBE, XRT, and XPH with low P/Es and fresh momentum are three undervalued ETFs to consider as 2026 approaches.

Zacks Investment Research • Dec 10, 2025

Pharma ETF (XPH) Hits a New 52-Week High

For investors seeking momentum, State Street SPDR S&P Pharmaceuticals ETF XPH is probably on the radar. The fund just hit a 52-week high and rose 61.4% from its 52-week low price of $35.22/share.

Zacks Investment Research • Dec 9, 2025

US, UK to agree to zero tariffs on pharmaceuticals, announcement expected, sources say

Britain and the United States are poised to agree to zero tariffs on pharmaceutical products, with an announcement due at the White House on Monday, according to two sources familiar with the matter.

Reuters • Dec 1, 2025

UK and US poised to agree zero-tariffs deal on pharmaceuticals, The Times says

The UK is poised to agree on a major pharmaceuticals deal with the U.S., which will mean zero import tariffs on pharmaceutical products into the U.S. and lead to an increase in NHS spending on medicines, The Times reported on Monday.

Reuters • Dec 1, 2025